Correction to: British Journal of Cancer (2018) 119, 282–290; 10.1038/s41416-018-0169-8; published online 11 July 2018.
The authors have noticed in Table 4 that the MT and P-value columns which should have appeared below the heading ‘Late sequelae independent of recurrent timepoint‘ have erroneously been listed under the ‘Late sequelae before recurrence‘ heading. The correct format of Table 4 is shown below.
Table 4.
Late sequelae by treatment group
| Late sequelae | Late sequelae independent of recurrence timepoint | Late sequelae before recurrencea | ||||
|---|---|---|---|---|---|---|
| ASCT | MT | P-valuea | ASCT | MT | P-valuea | |
| Intention to treat | % of 149 | % of 146 | % of 149 | % of 146 | ||
| Auditory impairment | 25 | 20 | 0.330 | 20 | 13 | 0.118 |
| Renal impairment | 8 | 10 | 0.550 | 6 | 7 | 0.816 |
| Thyroid dysfunction | 9 | 8 | 0.440 | 8 | 8 | 1.000 |
| Focal nodular hyperplasia of the liver | 6 | 1 | 0.019 | 6 | 1 | 0.019 |
| Hepatopathy | 4 | 1 | 0.121 | 3 | 1 | 0.214 |
| Peripheral neuropathy | <1 | <1 | 1.000 | 0 | <1 | 0.244 |
| Growth retardation | 2 | 3 | 0.721 | 1 | 3 | 0.444 |
| Cardiomyopathy | 0 | 2 | 0.120 | 0 | 2 | 0.120 |
| Residual transverse myelopathy | 0 | <1 | 0.495 | 0 | <1 | 0.495 |
| Persisting thrombocytopenia | <1 | <1 | 1.000 | <1 | <1 | 1.000 |
| Visual impairment | 2 | 3 | 0.498 | 1 | 2 | 0.682 |
| As treated | % of 110 | % of 102 | % of 110 | % of 102 | ||
| Auditory impairment | 31 | 21 | 0.116 | 21 | 19 | 0.732 |
| Renal impairment | 8 | 11 | 0.640 | 6 | 9 | 0.606 |
| Thyroid dysfunction | 12 | 7 | 0.247 | 11 | 7 | 0.344 |
| Focal nodular hyperplasia of the liver | 6 | 1 | 0.067 | 6 | 1 | 0.067 |
| Hepatopathy | 3 | 1 | 0.623 | 3 | 1 | 0.623 |
| Peripheral neuropathy | <1 | 0 | 1.000 | <1 | 0 | 1.000 |
| Growth retardation | 2 | 1 | 1.000 | 2 | 1 | 1.000 |
| Cardiomyopathy | 0 | 2 | 0.230 | 0 | 2 | 0.230 |
| Residual transverse myelopathy | 0 | 1 | 0.481 | 0 | 1 | 0.481 |
| Persisting thrombocytopenia | <1 | 0 | 1.000 | <1 | 0 | 1.000 |
| Visual impairment | 4 | 2 | 0.684 | 3 | 2 | 1.000 |
| Treated as randomised | % of 75 | % of 70 | % of 75 | % of 70 | ||
| Auditory impairment | 33 | 17 | 0.035 | 25 | 14 | 0.145 |
| Renal impairment | 9 | 11 | 0.787 | 7 | 9 | 0.759 |
| Thyroid dysfunction | 13 | 7 | 0.280 | 12 | 7 | 0.404 |
| Focal nodular hyperplasia of the liver | 9 | 1 | 0.064 | 9 | 1 | 0.064 |
| Hepatopathy | 4 | 1 | 0.621 | 4 | 1 | 0.621 |
| Peripheral neuropathy | 1 | 0 | 1.000 | 0 | 0 | n.a |
| Growth retardation | 0 | 1 | 0.483 | 0 | 1 | 0.483 |
| Cardiomyopathy | 0 | 3 | 0.231 | 0 | 3 | 0.231 |
| Residual transverse myelopathy | 0 | 1 | 0.483 | 0 | 1 | 0.483 |
| Persisting thrombocytopenia | 0 | 0 | N.A. | 0 | 0 | N.a. |
| Visual impairment | 3 | 3 | 1.000 | 3 | 3 | 1.000 |
a Late sequelae after the recurrence of neuroblastoma omitted